--- title: "Bionano Genomics (BNGO) news: convertible notes" url: "https://aibio.space/companies/bionano-genomics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BNGO convertible notes news: Bionano reports second quarter 2026 revenue of $8.2 million. Bionano Genomics, Inc. (NASDAQ: BNGO), United States." --- BNGO Bionano Genomics, Inc. NASDAQ · United States # Bionano Genomics (BNGO) news BNGO convertible notes news Company Updates · 2026-08-10 ## [Bionano reports second quarter 2026 revenue of $8.2 million](https://aibio.space/news/bionano-reports-second-quarter-2026-revenue-8-2-million/) Consumables revenue rose 31%, and the company completed the retirement of its senior secured convertible debentures. ## Latest Bionano Genomics news 1. 2026-05-13 Company Updates [Bionano reports first quarter 2026 revenue of $6.7 million](https://aibio.space/news/bionano-reports-first-quarter-2026-revenue-6-7-million/) Consumables revenue grew 20%, and the company guided to full-year 2026 revenue of $30 to $33 million. ## Bionano Genomics at a glance - **Ticker**: BNGO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $9.9 million ### Related companies - [GE HealthCare Technologies](https://aibio.space/companies/ge-healthcare-technologies/) NASDAQ: GEHC - [Adagio Medical Holdings](https://aibio.space/companies/adagio-medical/) NASDAQ: ADGM - [Outset Medical](https://aibio.space/companies/outset-medical/) NASDAQ: OM - [Lumexa Imaging Holdings](https://aibio.space/companies/lumexa-imaging/) NASDAQ: LMRI - [ALPHA PRO TECH LTD](https://aibio.space/companies/alpha-pro-tech/) NYSE: APT - [ALR Technologies SG](https://aibio.space/companies/alr-technologies-sg/) OTC: ALRTF - [Tilray Brands](https://aibio.space/companies/tilray-brands/) NASDAQ: TLRY - [InfuSystem Holdings](https://aibio.space/companies/infusystem/) NYSE: INFU ### Also on NASDAQ - [Keros Therapeutics](https://aibio.space/companies/keros-therapeutics/) KROS - [Bon Natural Life](https://aibio.space/companies/bon-natural-life/) BON - [Pliant Therapeutics](https://aibio.space/companies/pliant-therapeutics/) PLRX - [Inhibrx Biosciences](https://aibio.space/companies/inhibrx-biosciences/) INBX - [TransCode Therapeutics](https://aibio.space/companies/transcode-therapeutics/) RNAZ - [CARLSMED, INC.](https://aibio.space/companies/carlsmed/) CARL ## Bionano Genomics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$11.4 million](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000007/) | [$24.8 million](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000007/) | | Net income (loss) | [-$26.4 million](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000007/) | [-$112.0 million](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000007/) | | Cash from operations | [-$16.3 million](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000007/) | [-$68.9 million](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000007/) | | Cash and equivalents | [$3.0 million](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000044/) | [$9.2 million](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000007/) | | Short-term investments | [$16.3 million](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000044/) | [$302,000](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000007/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.7 million, plus short-term investments of $6.2 million, $9.9 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Bionano Genomics Has Bionano Genomics sold convertible notes? Our latest story on this, dated Aug 10, 2026: "Bionano reports second quarter 2026 revenue of $8.2 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bionano-reports-second-quarter-2026-revenue-8-2-million/). What is the ticker symbol of Bionano Genomics? Bionano Genomics, Inc. trades under the ticker BNGO on NASDAQ. Where is Bionano Genomics listed? Bionano Genomics, Inc. is listed on NASDAQ. Which country or territory is Bionano Genomics listed under? Our directory records Bionano Genomics, Inc. under United States. Does aibio.space cover Bionano Genomics? aibio.space lists Bionano Genomics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Is Bionano Genomics profitable? Bionano Genomics, Inc. reported a net loss of $26.4 million for the fiscal year ended Dec 31, 2025, and used $16.3 million of cash in operations, per its annual report to the SEC. How much does Bionano Genomics spend on research and development? $11.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Bionano Genomics have? $9.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Bionano Genomics (BNGO) stock news? Our latest story on Bionano Genomics, dated Aug 10, 2026: "Bionano reports second quarter 2026 revenue of $8.2 million". Consumables revenue rose 31%, and the company completed the retirement of its senior secured convertible debentures. [Source](https://aibio.space/news/bionano-reports-second-quarter-2026-revenue-8-2-million/). How can I follow Bionano Genomics (BNGO) news? Press Follow on this page to add Bionano Genomics to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming Bionano Genomics so far, in Company Updates. ## Investor discussion: Bionano Genomics Members talk about Bionano Genomics (BNGO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Bionano Genomics, newest first. Each line links the filing it comes from. 1. 2026-10-27 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1411690/000119312526434439/bngo-20261027.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BNGO on TradingView](https://www.tradingview.com/symbols/NASDAQ-BNGO/). ## Listing details Bionano Genomics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BNGO, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Bionano Genomics, Inc. - **Ticker**: BNGO - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/bionano-genomics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Bionano Genomics (BNGO) news: convertible notes", 2026-10-31, https://aibio.space/companies/bionano-genomics/